Drug reference
ansuvimab
single human mAb · Ebola virus infection treatment
single human mAbEbola virus infection treatment
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Ansuvimab is a single human monoclonal antibody that effectively treats Ebola virus infection, demonstrating a reduction in mortality rate from approximately 70% to 34% in clinical use.
Indications
treatment of Ebola virus infection in adults and childrentreatment of Zaire ebolavirus
Pharmacokinetics
Half-life
~24 days (consistent with IgG antibodies)
Related guidelines
Hepatitis B — chronic infection
EASL · Gastroenterology · 2025
Skin and soft tissue infections
IDSA · Infectious Diseases · 2010
Urinary tract infection
EAU · Urology · 2024
Childhood pneumonia and respiratory infection
MOHFW · Paediatrics · 2021
Latent tuberculosis infection
RNTCP · Infectious Disease · 2023
Ask House about ansuvimab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team